Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo
Information source: Pamukkale University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Nausea; Vomiting; Vertigo
Intervention: Dimenhydrinate (Drug); Metoclopramide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Pamukkale University Official(s) and/or principal investigator(s):
Bulent ERDUR, proffessor, Study Director, Affiliation: Pamukkale University
Summary
- Vertigo complaint is one of the common cause of patients who applied to emergency
services.
- Patients who have applied to emergency services with vertigo complaint mostly have
nausea as an additionally symptom to this complaint and anti-emetic agents can be used
in their treatments very often.
- The investigators purpose is to investigate the advantages of Dimenhydrinate and
metoclopramide to each other in the treatment of vertigo and the vertigo accompanied by
nausea
Clinical Details
Official title: Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: compare the effects of intravenous dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo in emergency setting. (nausea and vertigo scores as measured by Visual Analogue Scale.)
Detailed description:
- Vertigo describes the illusion of being subject to an involuntary movement, usually
rotational, of the patient or the patient's surroundings which is caused by sudden
tonic neural activity.
- The management and episodic treatment of patients with spontaneous vertigo related
nausea-vomiting symptoms are somewhat controversial in the emergency department
setting.
- Patients admitted to the emergency department with complaints of vertigo in addition to
a large portion of the symptoms are accompanied by nausea and antiemetic agents are
frequently used in the treatment.
- An ideal treatment should be rapid in onset and effective, and lack debilitating side
effects.
- Although a wide variety of classes of pharmacologic agents and modalities are used, the
emergency department treatment of acute spontaneous vertigo and associated with nausea-
vomiting has not been well studied.
- It has been reported that the most commonly used medications for parenteral treatment
of vertigo and nausea-vomiting in emergency department are dimenhydrinate (DMT) and
metoclopramide (MTP).
- It has a depressant action on hyper-stimulated labyrinthine function and antiemetic
effects, believed to be due to the antihistamine.
- Dimenhydrinate inhibits vomiting by affecting the histaminic receptor and cholinergic
receptor function center of vestibular nucleus in the central vestibular system.
- Dimenhydrinate reduces the symptoms of vertigo with depressant effects on the labyrinth
function by this means.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- between 18 to 65 years old patients,
- had vertigo and accompanied nausea or vomiting [VAS (visual analog scale) score >5]
during their emergency department episode of care for which the attending physician
recommended intravenous antiemetic medication.
Exclusion Criteria:
- abnormal vital signs,
- women who were pregnant or lactation,
- those with a history of epilepsy,
- acute psychiatric symptoms,
- organic brain disease,
- parkinson's disease or phaeochromocytoma,
- or any known allergy to the study drugs,
- uncooperative individuals,
- use of any antiemetic drug in the previous 8 hours or previous delivery of
intravenous fluids during the emergency department episode of care,
- currently undergoing chemotherapy or radiotherapy,
- mechanical obstruction or perforation,
- gastrointestinal bleeding,
- inability to understand study explanation or outcome measures (any reason),
- known allergy or previous adverse reaction to metoclopramide or dimenhydrinate,
- and patients who refused to participate study.
Locations and Contacts
Additional Information
Starting date: November 2012
Last updated: September 27, 2014
|
